{"id":"W4387810308","doi":"10.1016/j.annonc.2023.09.2759","title":"1811P Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from a phase III (TALAPRO-2) study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Pharmaceuticals; Foundation Medicine; Pharmacyclics; Takeda Oncology; Chugai Pharmaceutical; EMD Serono; Genentech; Ipsen; PharmaMar; Novartis Farmacéutica; Astellas Pharma; Eisai; Plexxikon; Seagen; UroGen Pharma; Pfizer; Incyte; Arog Pharmaceuticals; Exelixis; Karyopharm Therapeutics; MEI Pharma; Clovis Oncology; Gilead Sciences; Calithera Biosciences; Celldex Therapeutics; Boston Scientific Corporation; Bayer Yakuhin; Novartis; Astellas Foundation for Research on Metabolic Disorders; Endocyte; Merck KGaA; Sanofi; Cilag; Puma Biotechnology; Advanced Accelerator Applications; Janssen Biotech; Teva Pharmaceutical Industries; Amgen; Myriad Genetics; ImmunoMedics; Eli Lilly and Company; Invitae; AstraZeneca; Lantheus Medical Imaging","keywords":"Enzalutamide; Medicine; Prostate cancer; Oncology; Internal medicine; Placebo; Cancer; Androgen receptor; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008854509,0.0006373656,0.0009480936,0.0002441218,0.0001809529,0.0006174581,0.0003374559,0.0005212965,0.002221404],"category_scores_gemma":[0.0007666265,0.0001900605,0.001797098,0.0004727902,0.0002682178,0.0004749417,0.0003212497,0.001267506,0.0002997132],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003535726,"about_ca_system_score_gemma":0.0002758453,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005575021,"about_ca_topic_score_gemma":0.001429382,"domain_scores_codex":[0.9996797,0.0001538364,0.00001750911,0.00005938963,0.00004673733,0.00004292513],"domain_scores_gemma":[0.9994695,0.0001448436,0.0002282284,0.00002281049,0.00002609346,0.000108478],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6515362,0.004112609,0.1503532,0.002500614,0.01613221,0.0003206312,0.0001681545,0.006338184,0.00849382,0.0005495834,0.006029621,0.1534653],"study_design_scores_gemma":[0.1201784,0.136182,0.7073416,0.000305246,0.0188012,0.0007972107,0.000249759,0.005037398,0.002919935,0.001341493,0.006709949,0.0001358198],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9879789,0.007284308,0.0001752605,0.0003188477,0.00009349535,0.000095982,0.002138764,0.00002774039,0.001886668],"genre_scores_gemma":[0.9947317,0.001755742,0.0001907379,0.0002953375,0.0001062851,0.0001018014,0.001928517,0.000006395365,0.0008835903],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002221404,"threshold_uncertainty_score":0.007431328,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07905098879133958,"score_gpt":0.4067292390465667,"score_spread":0.3276782502552271,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}